Prakt. lékáren. 2019; 15(2): 106-110

Terapie rhinitidy

Vilma Vranová, Karel Vašut
Ústav aplikované farmacie, Farmaceutická fakulta VFU Brno

Published: June 20, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vranová V, Vašut K. Terapie rhinitidy. Praktické lékárenství. 2019;15(2):106-110.
Download citation

References

  1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the Health Organization, GA (2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86): 8-160. Go to original source...
  2. Braunstahl G-J, Fokkens WJ. Nasal involvement in allergic astma. Allergy 2003; 58: 1235-1243. Go to original source...
  3. Okano M.: Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clinical and Experimental Immunology. 2009, 158, 164-173 Go to original source...
  4. Barnes j.P.: Inhaled Corticosteroids. Pharmaceuticals 2010, 3(3), 514-540 Go to original source... Go to PubMed...
  5. Bystroň J. Léčba alergických onemocnění. Prakt. Lékáren. 2011; 7(2): 63-67.
  6. Derendorf, H. and Meltzer, E. O. (2008), Molecular and clinical pharmacology of intrana-sal corticosteroids: clinical and therapeutic implications. Allergy, 63: 1292-1300 Go to original source...
  7. Potter PC, Pawankar R.: Indications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitis. The World Allergy Organization journal. 2012, 5(Suppl 1): S14-S17 Go to original source...
  8. Rottenberg J.: Nazální kortikoidy v léčbě rýmy. Praktické Lékárenství 2016; 12(6): 227-230 Go to original source...
  9. Hrubiško M.: Topické kortikosteroidy v klinickej praxi z pohľadu účinnosti a bezpečnosti. Via practica, 2012, 9, 1
  10. Krčmová I.: Nazální kortikosteroidy a ovlivnění očních příznaků alergické rhinitidy. Reme-dia 2009; 19: 26-33.
  11. Sastre J., Mosges R.: Local and Systemic Safety of Intranasal Corticosteroids. J Investig Allergol Clin Immunol 2012; Vol. 22(1): 1-12
  12. Passali, D., Salerni, L., Passali, G. C., Passali, F. M., Bellusi, L.: Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opinion on Drug Safety, 2006, 5-6, p. 783-790. Go to original source... Go to PubMed...
  13. Fowler PD, Gazis AG, Page SR, Jones NS. A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol Allied Sci. 2002; 27(6): 489-493. Go to original source... Go to PubMed...
  14. Mygind N, Lund V. Intranasal corticosteroids for nasal polyposis: biological rationale, efficacy, and safety. Treat Respir Med. 2006; 5(2): 93-102. Go to original source...
  15. Chong L, Head K, Hopkins C, Philpott C, Schilder AGM, Burton MJ. Intranasal steroids ver-sus placebo or no intervention for chronic rhinosinusitis. Cochrane Database of Systema-tic Reviews 2016, Issue 4. Art. No.: CD011996. DOI: 10.1002/14651858.CD011996.pub2 Go to original source...
  16. Rodrigo, G. J., and H. Neffen. "Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review." Cli-nical & Experimental Allergy 41.2 (2011): 160-170. Go to original source...
  17. Seberová E. Chronická rinitida. In: Špičák V, a kol. Alergologie. Galén Praha 2004: 175-187.
  18. Adelsberg J, Philips G, Pedinoff EO, et al. Montelukast improves symptom of seasonal allergic rhinitis over 4-week treatment period. Allergy 2003; 58: 1268-1276 Go to original source...
  19. Hloch K, Doseděl M: Alergická rýma - jak může pomoci lékárník. Prakt. Lékárenství 2017, 13, 1, 30-35 Go to original source...
  20. Krčmová I: Alergická rýma - klinické aspekty a léčba. Klin. Farmakologie a farmacie 2011, 25, 4, 177-183
  21. Bystroň J: Moderní léčba alergické rýmy v ordinaci praktického lékaře. První linie. 2015, 5, 1, 16-22
  22. Bystroň J: Antihistaminika v léčbě alergického zánětu. REMEDIA, 2014, 24, 4, 272-278




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.